Israeli medical imaging technology company Nanox has signed an exclusive distribution agreement with Golden Vine to debut its medical imaging services in Taiwan and Singapore.

Upon obtaining required regulatory approvals and acceptance test clearance, both companies will collaborate on the deployment and operation of 500 Nanox Systems comprised of the Nanox.ARC and the Nanox.CLOUD.

The partnership is aimed at providing medical imaging services across Taiwan at affordable prices.

In conjunction with the agreement, Golden Vine will commit to a minimum annual service fee of $28.9m.

Nanox founder and CEO Ran Poliakine said: “Taiwan is one of the most advanced countries in the world for innovative healthcare. Our collaboration with Golden Vine and Ms Liao is aimed to create a countrywide centre of excellence for 21st-century early-detection imaging methodologies and use of AI for preventive healthcare.”

Currently, medical imaging is the primary non-invasive diagnostic tool in Taiwan. Through the partnership, Nanox aims to help address increased accessibility and diagnostics needs in the country.

The systems offer a range of medical imaging services such as 2D X-ray and 3D tomosynthesis computed tomography. The company expects to operate the services in a pay-per-scan business model.

Golden Vine CEO Pepi Liao said: “We believe Nanox can provide a strong solution for mass-population screening and, in special situations such as Covid-19, Nanox can be the game-changing factor where millions of people need to undergo imaging in a short time and are facing an insufficient install base to accommodate such a scenario.

“We have many challenges ahead, but our aim is to become a prime service provider for preventive healthcare and drive innovation throughout the Asia Pacific.”